PASG Q2 2025 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena

PASGPassage Bio, Inc.

$29M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$200,000

Operating Income

-$10M

Net Income

-$9M

EPS (Diluted)

$-2.96

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$923,000

Balance Sheet

Total Assets

$79M

Total Liabilities

$41M

Stockholders' Equity

$38M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$200,000	$0	—
Operating Income	-$10M	-$17M	+40.5%
Net Income	-$9M	-$16M	+41.3%